Experimental obesity drug Qnexa helps diabetics

Qnexa was shown to improve blood sugar control through weight loss in obese patients with type 2 diabetes. The one-year trial results for the weight loss drug sent the company's shares up nearly 6 percent after hours. The study also showed that Qnexa had a positive impact on other risk factors associated with diseases prevalent in people living with diabetes, according to Vivus.
The trial showed that patients treated with Qnexa achieved a 1.6 percent reduction in hemoglobin A1c, a key indicator of blood sugar control, compared with a drop of 1.1 percent in the placebo group.

Patients taking Qnexa also lost an average of 9.4 percent of their body weight, compared with 2.7 percent for the placebo group. In addition, the study showed that Qnexa had a positive impact on other risk factors associated with diabetes, including blood pressure and triglycerides. Data from the study was presented during the American Diabetes Association’s annual meeting in New Orleans.
Source: Reuters